Develops investigational medicines for people with depression, Alzheimer’s disease agitation, schizophrenia, obesity and other brain-related disorders.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward…View ↗
Navacaprant is a novel, oral once-daily, selective kappa opioid receptor (“KOR”) antagonist in development for the monotherapy treatment of…View ↗
NMRA-898View ↗
NMRA-215View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 16, 2026
−$34.4MView ↗
8-K, filed Oct 30, 2026
On October 26, 2026, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)…View ↗
8-K, filed Aug 14, 2026
On August 14, 2026, the Company announced that Paul L. Berns, the Company’s current Chief Executive Officer, will become the Company’s…View ↗
8-K, filed Jun 15, 2026
On June 15, 2026, the Company announced that the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive…View ↗
Competes with Axsome Therapeutics, Denali Therapeutics, Neurocrine Biosciences, Prothena, and Xenon Pharmaceuticals
10-K for FY2025, filed Mar 30, 2026Neumora is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally…View ↗
Loading...